🇺🇸 FDA
Patent

US 12163148

Directed editing of cellular RNA via nuclear delivery of CRISPR/Cas9

granted A61KA61K48/00A61P

Quick answer

US patent 12163148 (Directed editing of cellular RNA via nuclear delivery of CRISPR/Cas9) held by The Regents of the University of California expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K48/00, A61P, A61P21/00